|drug3769||acute kidney injury Wiki||1.00|
There is one clinical trial.
A Phase I open label followed by a Phase II randomized, controlled study to assess the efficacy and safety of ABTL0812 in combination with FOLFIRINOX for first-line treatment of metastatic pancreatic
Description: Recommended Phase II Dose (RP2D) of ABTL0812 in combination with FOLFIRINOXMeasure: RP2D Time: 6 months
Description: PFS using RECIST v1.1 by investigator analysisMeasure: PFS Time: 1 year
Description: Objective response rate (ORR)Measure: ORR Time: 1 year
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports